GLP-1 receptor agonists (GLP-1RAs) were initially developed for glycemic control in type 2 diabetes but have now shown benefits in weight reduction, cardiovascular outcomes, and potentially NAFLD. Newer agents like semaglutide and tirzepatide (a dual GIP/GLP-1 agonist) have demonstrated substantial metabolic improvements. Endocrinologists are increasingly using these agents in patients with obesity and metabolic syndrome, even without diabetes. The mechanisms of action of GLP-1RAs include delayed gastric emptying, central appetite suppression, and improved insulin sensitivity.
Let’s assess your command over this transformative drug class. Scroll down to answer a quick question on GLP-1 RAs! Reference : Nature Reviews Cardiology ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or…
